What is the difference between PIC/S, EU GMP and WHO guidelines? It is one of the most common questions for QA professionals, Qualified Persons and anyone preparing audits across different markets: three "families" of GMP that look very similar, yet differ in nature, legal status and scope of application. Confusing them can be costly — for instance citing the wrong reference in an SOP, or walking into a WHO inspection with an EudraLex-only mindset. In this guide we compare the three frameworks, explain when each one applies, and show how to manage multi-standard compliance in an audit-ready way.
Difference Between PIC/S, EU GMP and WHO Guidelines: the Three Frameworks at a Glance
Let's start with who the three actors are:
- EU GMP (EudraLex Volume 4): the European Union's GMP, binding on manufacturing authorisation holders in the EU/EEA. It is structured into Part I (medicinal products), Part II (active substances), Part III (supporting documents) and the Annexes (from Annex 1 on sterile products to Annex 16 on QP certification). Enforcement lies with the national competent authorities.
- PIC/S (Pharmaceutical Inspection Co-operation Scheme): not a legislator but a co-operation scheme between inspection authorities, currently counting 57 Participating Authorities across Europe, the Americas, Asia, Africa and Australasia. Its mission is to harmonise GMP standards and the quality systems of inspectorates. Its main instrument is the PIC/S GMP Guide PE 009 (current version PE 009-17), complemented by the PI documents for inspectors.
- WHO GMP: the World Health Organization's good manufacturing practices, whose core text is "WHO good manufacturing practices for pharmaceutical products: main principles" (TRS 986, Annex 2, 2014). They are the reference for WHO prequalification (essential for supplying UN agencies and global health programmes) and are adopted or referenced by many national authorities that are not PIC/S members.
Nearly Identical Content, Different Legal Status
The point that generates the most confusion: the PIC/S GMP Guide and EU GMP largely overlap. PE 009 historically derives from the European guide and follows its structure (Part I, Part II, Annexes); revision PE 009-17, in force since 25 August 2023, incorporated the new Annex 1 on sterile products, which entered into operation on the same day as the EU Annex 1 and is identical to it apart from minor differences (for point 8.123 on lyophilisation, application was deferred to 25 August 2024, as in the EU).
The real difference is not in the content but in the status: EudraLex Volume 4 is connected to the EU legal framework and is therefore binding for European sites; the PIC/S GMP Guide is a harmonised standard that each participating authority applies under its own legal system (for many non-EU authorities it is de facto "the" national GMP). WHO GMP, finally, become binding when an authority adopts them into its own framework or when a company enters the WHO prequalification pathway.
Also beware of a recurring misconception: there is no "PIC/S certificate" issued to companies. PIC/S accredits and connects authorities; GMP certificates are still issued by individual authorities (EU agencies, FDA, TGA...), whose mutual reliance is, however, facilitated precisely by membership of the scheme.
If you navigate daily between EudraLex, PIC/S and international requirements, The Pragmatic GMP is the free weekly newsletter made for you: every week one GxP topic explained in a practical, audit-ready way. Subscribe so you don't miss the next deep dives.
Comparison Table: PIC/S vs EU GMP vs WHO
| Aspect | EU GMP (EudraLex Vol. 4) | PIC/S (PE 009) | WHO GMP (TRS 986 Annex 2) |
|---|---|---|---|
| Nature | Requirements linked to the EU legal framework | Harmonised standard across 57 inspection authorities | International guidelines issued by WHO |
| Applies to | Authorised manufacturers in the EU/EEA (and imports into the EU) | Sites inspected by participating authorities that have adopted it | WHO prequalification; countries adopting it as their national reference |
| Structure | Parts I, II, III + Annexes 1-21 | Introduction, Part I, Part II + Annexes (aligned with the EU Annexes) | Main principles + dedicated WHO guideline series (water, HVAC, validation...) |
| Updates | European Commission / EMA | PIC/S Committee, generally following EU revisions (e.g. Annex 1 in force the same day) | WHO Expert Committee (TRS series) |
| Typical inspections | EU national authorities | Non-EU PIC/S authorities (TGA, HSA, MFDS, ANVISA...) | WHO prequalification teams, authorities applying WHO GMP |
What Changes in Practice for QA and QPs
For a European exporting site, the typical picture is this: the compliance baseline is EudraLex Volume 4; an inspection by Australia's TGA or another PIC/S authority will run on nearly identical PE 009 requirements, with a focus on the PI documents inspectors use; supplying UN agencies or global health programmes will instead require demonstrating compliance with WHO GMP, which have their own structure and terminology.
The concrete benefit of PIC/S harmonisation is fewer duplicated inspections: many participating authorities rely on each other's inspection outcomes, and a site already inspected by one PIC/S authority starts at an advantage with the others. This does not eliminate specificities, though: each authority keeps its own practices, its own forms and — above all — its own interpretation of critical points.
The operational differences to keep under control are mainly three:
- Document references: SOPs, VMPs and quality agreements must cite the correct framework for each market; copy-pasting EudraLex references into a dossier intended for a WHO-based authority is an easy finding.
- Transposition timing: PIC/S Annexes follow EU revisions, but the transition is not always simultaneous for every document; always verify the version in force at the inspecting authority.
- Satellite guidelines: WHO complements its main principles with dedicated guidelines (water for pharmaceutical use, HVAC, technology transfer) that have no 1:1 equivalent among the EU Annexes; in a prequalification inspection they can be explicitly invoked.
GuideGxP Recommendation
Build a multi-standard compliance matrix: your processes on the rows (sterile manufacturing, validation, data integrity, batch release...), the three frameworks on the columns with precise references (EU chapter/Annex, PE 009 section, TRS section). Highlight only the real gaps — they are few but critical — and link the matrix to regulatory change control: whenever an EU Annex or a WHO guideline is revised, the matrix is updated and the impacted SOPs reviewed. In an audit, this document demonstrates within minutes that the site governs multi-market compliance instead of enduring it.
To master the Annexes at the heart of the comparison (1, 15, 16 and 20) and their operational implications, take a look at our Operational Guide to GMP Annexes 1, 15, 16 and 20 – With Best Practices: precise references, examples and audit-ready checklists.
